Notable Analyst Rating Changes 5/6: (SRPT) (AXP) (YNDX) Upgraded; (NSM) (DEI) (FNFG) Downgraded
Tweet Send to a Friend
UPGRADES
Baird upgraded Sarepta Therapeutic (Nasdaq: SRPT) from Neutral to Outperform and moved its price target from $16 to $20 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Baird upgraded Sarepta Therapeutic (Nasdaq: SRPT) from Neutral to Outperform and moved its price target from $16 to $20 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
